Nested Therapeutics Announces Nomination of First Development Candidate, a Potential First-in-Class Inhibitor of the RAS/MAPK Pathway

/PRNewswire/ -- Nested Therapeutics, a biotechnology company pioneering a next-generation precision medicine platform to address hard-to-treat cancers, today...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Klaus Hoeflich , ,Darrin Miles ,Chief Executive Officer ,Chief Scientific Officer ,Nested Therapeutics ,Nc ,